Microgestin 1.5/30 Generic Name & Formulations
Norethindrone acetate 1.5mg, ethinyl estradiol 30mcg (21 tabs).
Progestin + estrogen.
Packs (Fe 1/20, Fe 1.5/30)—3, 6; Packs (1/20, 1.5/30)—6
Microgestin 1.5/30 Indications
Microgestin 1.5/30 Dosage and Administration
28-day products: 1 tab daily for 28 days; repeat. 21-day products: 1 tab daily for 21 days, then 7 tablet-free days; repeat.
Microgestin 1.5/30 Contraindications
Thrombophlebitis or thromboembolic disorders. History of DVT, cerebrovascular or coronary artery disease. Known or suspected breast carcinoma, endometrial or other estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).
Microgestin 1.5/30 Boxed Warnings
Cigarette smoking increases risk of serious cardiovascular events.
Microgestin 1.5/30 Warnings/Precautions
Increased risk of cardiovascular events esp. in cigarette smokers >35yrs of age; not recommended. Discontinue if thrombotic event, unexplained visual changes, jaundice, or headache/migraine occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism, and during and after prolonged immobilization. Cardio- or cerebrovascular diseases. Gallbladder disease. Obesity. Diabetes. Prediabetes. Hypertriglyceridemia. Depression. Conditions aggravated by fluid retention; monitor. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea, retinal vein thrombosis. Monitor BP. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Nursing mothers: not recommended.
Microgestin 1.5/30 Pharmacokinetics
Microgestin 1.5/30 Interactions
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels.
Microgestin 1.5/30 Adverse Reactions
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.
Microgestin 1.5/30 Clinical Trials
Microgestin 1.5/30 Note
Microgestin 1.5/30 Patient Counseling